Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00921804 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schizophrenia Patients
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 296
- Enrollment target
NCT00921804: Completed Phase 2 study, sponsored by AstraZeneca.
NCT00921804 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 296 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (123% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00921804, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 296 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether treatment with daily oral dose of AZD8529 40 mg administered over 28 days is safe, well tolerated and improves main symptoms of schizophrenia in adult schizophrenia patients.
Interventions
- DRUG Risperidone
- DRUG Placebo to match AZD8529
- DRUG AZD 8529
- DRUG Placebo to match risperidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 296 participants |
| Start Date | 2009-06 |
| Est. Completion | 2010-05 |
| Phase | Phase 2 |
What the finished NCT00921804 record still lists
NCT00921804 is an interventional study that assigns participants to a tested intervention. The registered 296 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (123% higher).
The record links to 0 conditions, and to 4 interventions - of which Risperidone is the first listed.
NCT00921804 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00921804 about?
NCT00921804 is a clinical study titled "Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schizophrenia Patients". The purpose of this study is to determine whether treatment with daily oral dose of AZD8529 40 mg administered over 28 days is safe, well tolerated and improves main symptoms of schizophrenia in adult schizophrenia patients.
What is the current status of trial NCT00921804?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 296 participants. The study started on 2009-06. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00921804?
The interventions under investigation include: Risperidone (DRUG), Placebo to match AZD8529 (DRUG), AZD 8529 (DRUG), Placebo to match risperidone (DRUG).
Who is sponsoring clinical trial NCT00921804?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00921804's enrollment target sits among peer trials
296 189th of 2000 higher than 1,812 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05563792 · 296 participants · NA
Options for Pain Management Using Nonpharmacological Strategies
- NCT06828445 · 296 participants · Phase 1
Increasing Affordable Fruits and Vegetables for Families With Food Insecurity
- NCT06920563 · 296 participants · NA
Remote Postpartum Blood Pressure Monitoring and Cardiovascular Education
- NCT06309160 · 297 participants · NA
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia